AZN AstraZeneca PLC

   By Adriano Marchese 
 

AstraZeneca PLC said Thursday that the Phase 3 GY004 trial for its drug Cediranib didn't meet its primary endpoint.

The pharmaceutical company said that the trial didn't meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in progression-free survival with the drug.

In the trial, Cediranib was added to Lynparza in platinum-sensitive relapsed ovarian cancer.

"Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer," Executive Vice President of Oncology Research and Development Jose Baselga said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 12, 2020 03:44 ET (07:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.